anti-CD19 CAR T-Cell therapy (Guangdong Zhaotai Cell Biotech)

N/A

Report date: 2025/01/26 18:10:06

Base Information

Drug Nameanti-CD19 CAR T-Cell therapy (Guangdong Zhaotai Cell Biotech)
Drug Alias NameCAR-19T2 T cell therapyCAT-19T2
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFoshan Zhaotai Innovation Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFoshan Zhaotai Innovation Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A